Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca : 3Q Operating Profit Rises Despite Product Sales Decline

share with twitter share with LinkedIn share with facebook
share via e-mail
11/09/2017 | 08:55am CET

By Adam Clark

AstraZeneca PLC (AZN.LN) reported Thursday that its operating profit for the third quarter of 2017 increased, boosted by a one-off tax benefit, but product sales continued to decline due to the loss of exclusivity on some key drugs.

The pharmaceutical company's operating profit rose 12% to $1.15 billion, up 9% in constant currencies. Pretax profit rose 33% to $1.82 billion.

However, product sales for the quarter fell 3% to $4.88 billion, which AstraZeneca said was due to a loss of exclusivity on its Crestor and Seroquel products. Total revenue rose 9% to $6.23 billion, benefiting from a contribution from externalization revenue--proceeds from partnerships and licensing deals.

AstraZeneca narrowed its 2017 guidance, saying it now expects its core earnings per share to be towards the favorable end of a low to mid-teens percentage decline. It reiterated its 2017 revenue guidance of a low to mid single-digit percentage drop.

Chief Executive Pascal Soriot said the most notable developments of the quarter were positive data from the company's drugs pipeline, especially its Tagrisso and Imfinzi cancer therapy candidates.

Write to Adam Clark at [email protected]; @AdamDowJones

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
11/17 ASTRAZENECA : receives US FDA approval for Faslodex to treat advanced breast can..
11/16 ASTRAZENECA : Data on Eye Proteins Reported by Researchers at AstraZeneca (A pre..
11/16 ASTRAZENECA : New Pharmaceutical Research Data Have Been Reported by Researchers..
11/16 ASTRAZENECA : FDA approves Fasenra for severe eosinophilic asthma
11/16 ASTRAZENECA : shares up 1.2% after getting regulatory green light for asthma dru..
11/16 ASTRAZENECA : Fasenra (benralizumab) receives US FDA approval for severe eosinop..
11/16 ASTRAZENECA : First EU approval for fulvestrant in combination with a CDK4/6 inh..
11/16 ASTRAZENECA : s Fasenra scores US approval in severe asthma
11/16 Europe approves GlaxoSmithKline's new triple lung drug
11/15 ASTRAZENECA : FASLODEX® (fulvestrant) Receives US FDA Approval for the Treatment..
More news
News from SeekingAlpha
11/17 Denali Therapeutics Files To Raise $100 Million IPO
11/17 AstraZeneca in talks to settle Texas lawsuit over off-label Seroquel marketin..
11/17 AstraZeneca to present new late-stage data on cancer drugs at ESMO Asia
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/16 3 THINGS IN BIOTECH YOU SHOULD LEARN : November 16, 2017
Financials ($)
Sales 2017 21 797 M
EBIT 2017 5 886 M
Net income 2017 2 296 M
Debt 2017 12 460 M
Yield 2017 4,15%
P/E ratio 2017 33,09
P/E ratio 2018 27,76
EV / Sales 2017 4,38x
EV / Sales 2018 4,38x
Capitalization 83 091 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 68,1 $
Spread / Average Target 3,6%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA12.11%83 091
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550